Clinical Trial

Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion

Study acronym: CHIK-RE-VAC
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated July 29, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
Against the backdrop of a growing chikungunya epidemic in La Réunion, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ® vaccine in vulnerable individuals (seniors, comorbid patients), defined by the French Health Autority (HAS) as at risk of severe or complicated forms and/or chronic disabling forms (chronic arthritis, chronic fatigue phenotypes). This study will also provide input for the preparation of a cluster randomized trial on a population scale.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-08; most recent amendment 2025-07-28.
Status change: Not Yet Recruiting → Recruiting 2025-04-23
Trial Details
NCT Number NCT06928753
Lead Sponsor Centre Hospitalier Universitaire de la Réunion
Collaborators: ANRS, Emerging Infectious Diseases, Région La Réunion, ARS La Réunion, Direction Générale de l'Offre de Soins
Conditions Chikungunya Virus Infection
Enrollment 1,800 participants
Start Date 2025-04-18
Primary Completion 2026-04 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-07-29